DrugPatentWatch Database Preview
Details for Patent: 10,130,636
» See Plans and Pricing
Which drugs does patent 10,130,636 protect, and when does it expire?
Patent 10,130,636 protects RUBRACA and is included in one NDA.
This patent has seventeen patent family members in twelve countries.
Summary for Patent: 10,130,636
| Title: | High dosage strength tablets of rucaparib |
| Abstract: | A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one camsylate salt has been disclosed. |
| Inventor(s): | Etter; Jeffrey (Boulder, CO) |
| Assignee: | Clovis Oncology, Inc. (Boulder, CO) |
| Application Number: | 15/920,643 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 10,130,636
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,130,636
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015305696 | Start Trial | |||
| Australia | 2019272064 | Start Trial | |||
| Brazil | 112017000865 | Start Trial | |||
| Canada | 2955495 | Start Trial | |||
| China | 106794185 | Start Trial | |||
| European Patent Office | 3182975 | Start Trial | |||
| Israel | 249946 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
